http://web.archive.org/web/20140524105156id_/http://www.dailymail.co.uk/news/article-2636898/Pressure-mounts-AstraZeneca-major-shareholder-pushes-Pfizer-deal-wake-rejected-69bn-bid.html

by @entity0 @entity2 is facing mounting pressure from its shareholders to do a deal to sell itself to @entity7 rival @entity6 , it emerged last night			1
days after it rejected a £ 69billion bid for the company , the @entity10 drug maker ’s largest investor has urged it to return to the negotiating table			1
@entity7 mega-fund @entity14 , which owns a 7.8per cent stake in the company , has told the board it was wrong to walk away from talks			2
pensions funds and wealth managers accounting for around a sixth of its shares are believed to have urged the company ’s board of directors to re-open talks with the @entity7 predator			2
@entity7 mega-fund @entity14 , which owns a 7.8per cent stake in @entity2 , has told the board it was wrong to walk away from talks			2
earlier this week @entity33 rejected @entity6 ’s ‘ final ’ £ 69billion offer of £ 55 a share			1
the move all but guaranteed its independence because @entity6 is now banned from hiking its offer any further under @entity10 takeover law			1
but in three months ’ time the legal ban expires , which would allow the @entity33 board to re-engage with the @entity7 company			0
while @entity6 is not allowed to approach @entity2 unsolicited for at least six months , the @entity10 group can open fresh talks as early as august			1
it is widely expected that @entity33 will face increased pressure to try and strike a deal			0
the proposed takeover would be the largest ever of a @entity10 firm by a foreign company			2
but the deal has been widely criticised by scientists , @entity53 investors and mps			0
@entity33 ’s chief executive @entity56 told @entity51 the takeover risked delaying the development of life - saving drugs that @entity33 is currently working on			0
@entity6 has also been criticised for its takeover motives , which is to help whittle down its international tax bill by moving its base out of the @entity7			1
the @entity7 predator has almost 200 offshoots in tax havens , accounting for almost 40per cent of its international subsidiaries			0
according to reports , @entity14 told company directors they were right to reject the £ 55 a share offer , but said they should return to the deal - making table as soon as possible			1
the shareholder joins a chorus of critics that also include major investors @entity76 and @entity78			0
but other significant investors , such as @entity80 and @entity81 , have backed the board ’s decision to terminate the negotiations			0
@entity14 , @entity2 and @entity6 all refused to comment .			0

investor in @entity10 *dtrug* maker has urged it to return to negotiations
@entity7 firm @entity6 offered £ 55 a share , *totalling* £ 69billion

@entity2:AstraZeneca
@entity33:Astra
@entity14:Blackrock
@entity7:US
@entity6:Pfizer
@entity10:British
@entity53:City
@entity81:M&G
@entity51:MPs
@entity0:Peter Campbell
@entity56:Pascal Soriot
@entity76:AXA , Legal & General
@entity80:Fidelity
@entity78:Schroders